ArticleFrontiers in oncology2026
Tumor progression is effectively suppressed by miR-195 through direct targeting of YAP1.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Yes-associated protein 1 (YAP1) dysregulation is frequently observed in various human cancers. This study aimed to identify microRNAs (miRNAs) capable of suppressing YAP1 expression and to elucidate their functional roles in tumor progression. Methods: We screened five candidate miRNAs using a luciferase reporter assay containing the YAP1 3' untranslated region (3' UTR). Functional validation was performed using gain- and loss-of-function experiments in HCT116 and A549 cell lines. The Results: Among the tested miRNAs, miR-195 demonstrated the most potent suppression of YAP1 3' UTR activity. This interaction was direct and specific, as a mutation in the YAP1 3' UTR seed sequence abolished miR-195-mediated repression. Consequently, miR-195 overexpression significantly reduced endogenous YAP1 protein levels and suppressed the expression of its downstream target, CTGF. Functionally, miR-195 overexpression inhibited cell viability and reduced colony formation by approximately 40% in HCT116 cells, while miR-195 knockdown promoted proliferation. Rescue experiments confirmed that the anti-proliferative effects of miR-195 were dependent on YAP1 suppression. Conclusion: Our findings establish miR-195 as a critical tumor suppressor that directly targets YAP1, highlighting its potential as a therapeutic target in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.